Halozyme Therapeutics (HALO) Cash from Operations (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Cash from Operations data on file, last reported at 180078000.0 in Q1 2026.

• Cash from Operations for Q1 2026 came in at 180078000.0, up 16.77% year-over-year; the trailing twelve-month figure through Mar 2026 was 677415000.0 (up 34.45% YoY), and the FY2025 annual result was 651558000.0, up 36.01% from the prior year.
• Cash from Operations fell to 180078000.0 in Q1 2026 per HALO's latest filing, from 219029000.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 219029000.0 in Q4 2025 and troughed at 40225000.0 in Q2 2022.
• A 5-year average of 114081235.29 and a median of 102354000.0 in 2023 frame the typical range for Cash from Operations.
• The sharpest annual moves came in 2022 and 2023: Cash from Operations sank 42.8% in 2022, then jumped 90.15% in 2023.
• A 5-year view of Cash from Operations shows it stood at 82453000.0 in 2022, then advanced by 24.14% to 102354000.0 in 2023, then jumped by 74.36% to 178467000.0 in 2024, then grew by 22.73% to 219029000.0 in 2025, then fell by 17.78% to 180078000.0 in 2026.
• Business Quant data shows HALO's Cash from Operations at 180078000.0 in Q1 2026, 219029000.0 in Q4 2025, and 178597000.0 in Q3 2025.